Evidence map›Paper›PMID 20602760›Full record

Trial reportBMC clinical pharmacology2010

The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol.

Trevor Tanner, Sue Aspley, Andrew Munn, Tracy Thomas

2 registry-linked trialsAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC clinical pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05428293 phase1completednot on this mapstarted 2019, after this paper: background citation

Study of no Pharmacokinetic Interaction Between Ibuprofen 100 mg and Acetaminophen 125 mg, Suspension Administered Individually or in Combination, Single Dose in Healthy Subjects, Both Genders Under Fasting Conditions

TypeinterventionalSponsorLaboratorios Silanes S.A. de C.V.Ran2019 to 2019Enrolled42ConditionsHealthyArmsA1: Ibuprofen/Acetaminophen Fixed dose combination oral suspension (Laboratorios Silanes S.A. de C.V.), A2: Ibuprofen (Advil®, Pfizer S.A. de C.V.), A3: Acetaminophen (Tylenol®, from Janssen-Cilag, S.A. de C.V.)
NCT05428306 phase1completednot on this mapstarted 2018, after this paper: background citation

Pharmacokinetic Interaction Study Between Ibuprofen 200 mg and Acetaminophen 500 mg, Tablets Administered Individually or in Combination, Single Dose in Healthy Subjects, Both Genders Under Fasting Conditions

TypeinterventionalSponsorLaboratorios Silanes S.A. de C.V.Ran2018 to 2019Enrolled42ConditionsHealthyArmsA1: Ibuprofen/Acetaminophen Fixed dose combination (Laboratorios Silanes S.A. de C.V.), A2: Ibuprofen (Motrin®, Pfizer S.A. de C.V.), A3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. The Effect of Acetaminophen on Running Economy and Performance in Collegiate Distance Runners.International journal of environmental research and public health · 2022
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Paracetamol and pain: the kiloton problem.European journal of hospital pharmacy : science and practice · 2016
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Trevor TannerSimbec Research Ltd, Cardiff Road, Merthyr Tydfil, CF48 4DR, UK. trevor.tanner@simbec.co.uk
Sue Aspley
Andrew Munn
Tracy Thomas

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIbuprofen and paracetamol differ in their mode of action and related therapeutic effects, suggesting that combined administration may offer improved analgesia. Reported here are the results of two studies on the pharmacokinetic properties of a novel ibuprofen (200 mg) and paracetamol (500 mg) fixed-dose combination tablet.

methodsBoth studies were open-label, randomised studies in healthy volunteers: Study 1 was a four-way crossover, single-dose study; Study 2 was a two-way cross-over, repeat-dose study.

resultsPharmacokinetic parameters for ibuprofen and paracetamol were similar for the combination and monotherapy tablets (values falling within the 80% to 125% acceptable bioequivalence range) except for the rate of absorption of paracetamol from the combination (tmax), which was significantly faster compared with monotherapy (median difference 10 minutes; p < 0.05). Mean plasma concentrations of both drugs were higher, earlier, following administration of the combination tablet compared with monotherapy. Mean plasma levels at 10 and 20 minutes were 6.64 microg x mL(-1) and 16.81 microg x mL(-1), respectively, for ibuprofen from the combination, compared with 0.58 microg x mL(-1) and 9.00 microg x mL-1, respectively, for monotherapy. For paracetamol, mean plasma levels at 10 and 20 minutes were 5.43 microg x mL(-1) and 14.54 microg x mL(-, respectively, for the combination compared with 0.33 microg x mL(-1) and 9.19 microg x mL(-1), respectively, for monotherapy. The rate of absorption of both ibuprofen and paracetamol was significantly delayed when the combination tablet was administered in the fed versus fasted state; median delay was 25 minutes for ibuprofen (p > 0.05) and 55 minutes for paracetamol (p < 0.001). The pharmacokinetic parameters were comparable irrespective of whether the combination tablet was given twice or three times daily; systemic exposure was, however, approximately 1.4 times greater for both drugs when given three times daily.

conclusionsAdministration of ibuprofen and paracetamol in a fixed-dose combination tablet does not significantly alter the pharmacokinetic profiles of either drug, except for enhancing the rate of paracetamol absorption, offering potential therapeutic benefits in relation to the onset of analgesia. Concentrations of both drugs reached previously reported therapeutic levels when the combination tablet was administrated in the fed or fasted state. Three times daily dosing may offer enhanced therapeutic effect for longer than twice daily dosing.

Indexed as

AcetaminophenAdministration, OralAdolescentAdultAnalgesics, Non-NarcoticAnti-Inflammatory Agents, Non-SteroidalCross-Over StudiesDrug Administration ScheduleDrug CombinationsFastingFemaleHumansIbuprofenIntestinal AbsorptionMaleMiddle AgedAcetaminophenAnalgesics, Non-NarcoticAnti-Inflammatory Agents, Non-SteroidalDrug CombinationsIbuprofenTablets

Identifiers

PMID20602760
PMCPMC2906415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.